-

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 September 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins (Paris:ERF):

ANNEXE B

Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities

  1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF)
    EUROFINS SCIENTIFIC SE – E1013
  2. Identity of the notifier (if another person makes the notification on behalf of the issuer)
    N/A
  3. Total number of shares composing the share capital of the notifying issuer
    182,163,000
  4. Total number of voting rights attached to the shares composing the share capital of the notifying issuer, including the suspended voting rightsii
    367,239,838
  5. Origin of the changeiii
    - Cancellation of some class A beneficiary units
    - Purchase of treasury shares
  6. Date when the change occurred
    30 September 2025

i Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.
ii For further details on the total number of voting rights, please refer to point 1(b) of circular CSSF 08/349.
iii As, for example, a capital increase or reduction.

Contacts

Eurofins

Eurofins

BOURSE:ERF
Release Versions
English

Contacts

Eurofins

More News From Eurofins

Eurofins Scientific SE: Weekly Report on Share Repurchases from 02nd February to 06th February 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 02/02/2026 FR0014000MR3 10 000 68.3375 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 03/02/2026 FR0014000MR3 10 000 67.9091 XPAR EUROFINS SCIENTIFIC 529900JEHFM...

Eurofins Viracor BioPharma Expands Bioanalytical Capabilities

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical...

Eurofins CDMO Alphora Joins International Consortium Project to Advance Next Generation ADC Expression Platform

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is pleased to announce that its Canadian-based division is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support a research and development collaboration project focused on advancing a transformative approach for next-generation ADC (antibody-drug conjugate) production to meet the growing demand for targeted therapeutics. As part of this initia...
Back to Newsroom